Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: A Phase I Study Of Subcutaneous Recombinant Human IL-15 (S.C.rhIL-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL
Brief Summary:
Background:
Adult T-cell leukemia (ATL) is a rare blood cancer. Researchers want to see if a combination of two drugs - recombinant human interleukin 15 (rhIL-15) and alemtuzumab - is a better treatment for ATL.
Objectives:
To test if giving rhIL-15 combined with alemtuzumab improves the outcome of therapy for ATL. Also, to determine the safe dose of this combination and identify side effects and effects on the immune system.
Eligibility:
Adults 18 years and older with chronic or acute ATL who have not been helped by other treatments.
Design:
Participants will be screened with tests that are mostly part of their usual cancer care. They will sign a separate consent form for this.
Weeks 1 and 2: Participants will have a total of 10 visits. They will:
Week 3: Participants will stay in the clinic. They will: